System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Alessandra Mangia is an expert in Hepatology at Casa Sollievo della Sofferenza (Italy). As of October 2026, ScienceLeadR ranks Alessandra Mangia in the top 1% of experts worldwide for Hepatitis. Alessandra Mangia has authored 402 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 3 of them ongoing. SLR score: 1,586 (community average: 125). How the SLR is computed.

LeadR Profile

Alessandra Mangia Casa Sollievo della Sofferenza Italy
1 586 ScienceLeadR Reputation 1586

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Infectiology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1994 - 2026
Source: PubMed

Casa Sollievo della Sofferenza

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 402

Citations

Citations: 21 934 1st author: 88 Last author: 59 Unique author: 7

Main journals

J Hepatol 77
Hepatology 29
Dig Liver Dis 25
Gastroenterology 20
N Engl J Med 13

Best Journals

N Engl J Med 13
J Hepatol 10
Gastroenterology 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Direct-Acting Antivirals in Patients with Comorbidities for the Simplified Management of HCV Infection: An Expert Review with a Focus on Sofosbuvir-Velpatasvir.
PMID 42655672 — comorbidity, polypharmacy, pharmaceutical preparations, virology, sofosbuvir, therapeutics, antiviral agents, infections		Viruses20260
Steatotic liver disease and chronic viral hepatitis.
PMID 42022366 — liver diseases, non-alcoholic fatty liver disease, hepatitis, chronic, liver, viruses, prevalence, hepatitis		Clin Exp Hepatol20250
Predictive Value of Sustained Virologic Response at Week 4 in Patients with Hepatitis C Virus Infection Treated with Sofosbuvir/Velpatasvir.
PMID 41754612 — sexually transmitted diseases, hepatitis c, virology, predictive value of tests, sustained virologic response, sofosbuvir, viruses, therapeutics, infections, hepatitis, virus diseases		Viruses20260
Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study.
PMID 41305413 — comorbidity, pharmaceutical preparations, therapeutics, antiviral agents, hepatitis		Pathogens20250
A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis.
PMID 41108609 — non-alcoholic fatty liver disease, liver, biomarkers, peroxidase		Liver Int20250

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Director: 1

By phase:

Phase 3 10
N/A 6
Phase 2 5

By status:

Completed 14
Active not recruiting 4
No longer available 1
Recruiting 1
Terminated 1

By type:

Interventional 15
Observational 5
Expanded Access 1

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 1
multicentricup10 16

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non Cirrhotic Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00 — safety, fibrosis, non-alcoholic fatty liver disease, alcoholics		Phase 3Recruiting2024
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis
NCT05627362 — bile, cholangitis, safety, pharmaceutical preparations, bile ducts, tablets, liver, cholangitis, sclerosing		Phase 2Active not recruiting2022
Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH)
NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS